An essential addition from discovery to approval in clinical development

23rd - 24th March 2010, BSG Conference Centre, London, UK

Pharmaceutical and biotech companies are looking for new ways to increase the efficiency of drug discovery process while minimising costs and time for approvals. Biomarkers are fast becoming an essential part of clinical development from discovery to approval. According to industry research, the global biomarker market is estimated to be $20.5 billion by 2014, growing at a CAGR of 19.7 %.

Additionally, the use of proteomics in biomarker testing and identification has boosted the services for biomarkers. A large number of companies now have commercialised biomarker tests employing a variety of technologies. However, there are several barriers and challenges that must be overcome behind these technologies.

Visiongain is proud to present its 3rd Annual Biomarker Conference, which will be held in London UK on 23-24 March 2010.This conference will enable you to identify and overcome challenges on how to incorporate biomarkers into your discovery programs as well as highlighting new technologies and strategies to improved prevention and care approaches.

more details…